FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune ®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ ...
A large-scale study has identified dozens of blood proteins linked to prostate cancer risk, some shared across populations, some unique to specific groups.
The combination therapy targets numerous mechanisms of cancer, promoting in situ immune activation while also battling immune suppression and minimizing systemic drug exposure. The goal is to activate ...
SYNC-T SV-102 Therapy combines partial tumor oncolysis with a fixed-dose combination multi-target biologic drug to provide a novel, personalized therapeutic approach for the treatment of metastatic ...
New York, NY (October 30, 2025) - A small, early clinical trial led by the Icahn School of Medicine at Mount Sinai and collaborators has shown that directly injecting an immune-activating compound ...
The state of prostate cancer in the U.S. is not exactly great. Just take a look at the “Prostate cancer statistics, 2025” report from the American Cancer Society, published at the beginning of ...
Share on Pinterest A supplement of vitamin K, which can also be found in leafy greens, such as kale, has shown promise in slowing down prostate cancer progression in mice. Image credit: BRETT ...
Former President Biden has been diagnosed with an aggressive form of prostate cancer. Among men in the U.S., prostate cancer is the most common cancer and the second leading cause of cancer deaths.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback